Skip to main content

Astrazeneca PLC 6-K, filed Oct 27, 2026

Astrazeneca PLC (AZN)

6-K 2026-10-27 For: 2026-10-27
View Original
Added on October 27, 2026

About this 6-K

Astrazeneca PLC filed this 6-K on October 27, 2026.

AstraZeneca and Daiichi Sankyo’s Enhertu won EU approval on 27 October 2026 for residual HER2-positive early breast cancer; DESTINY-Breast05 showed a 53% reduction in recurrence or death, and a $75 million milestone is due to Daiichi Sankyo. AI summary